Abciximab reduces nonfatal outcomes as part of a new reperfusion regimen for acute myocardial infarction (MI) but appears not to benefit patients with acute coronary syndromes who don't undergo early revascularization.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Trio of new studies help clarify role of abciximab

Newsletter